Travere Therapeutics, Inc. Common Stock
TVTX
$55.95
+1.52%
Travere Therapeutics is a biopharmaceutical company focused on developing and delivering therapies for rare kidney, liver, and metabolic diseases. The company is a specialized player in the orphan drug space, with its distinct identity built around its late-stage investigational product, sparsentan, for rare kidney disorders. The current investor narrative is overwhelmingly driven by the recent clinical and regulatory success of sparsentan, as evidenced by the stock's explosive 282.7% one-year price appreciation, which reflects market anticipation of its commercial launch and potential to address significant unmet medical needs in focal segmental glomerulosclerosis and IgA nephropathy.…
TVTX
Travere Therapeutics, Inc. Common Stock
$55.95
Investment Opinion: Should I buy TVTX Today?
Rating: Hold. The core thesis is that while sparsentan's potential is transformative and partly reflected in the 282.7% price surge, the stock now trades at a valuation that demands flawless execution, leaving asymmetric risk to the downside.
Supporting evidence includes the forward P/E of 11.36x, which prices in the analyst consensus for profitability, and the high gross margin of 97.89% that supports future earnings leverage. However, these positives are counterbalanced by a high debt load (D/E of 2.86), current unprofitability (negative net margin), and the stock's extreme technical position at 98.5% of its 52-week high after a parabolic move. The limited analyst coverage (4 analysts) with a wide revenue estimate range ($1.53B to $2.11B) underscores the high uncertainty.
The thesis would upgrade to a Buy on a meaningful pullback that better compensates for the binary risk, or upon confirmation of stellar initial sparsentan sales that meet the high end of estimates. It would downgrade to a Sell if the launch stumbles, debt concerns escalate, or the stock breaks key technical support. Based on the current data, the stock appears fully valued to slightly overvalued, pricing in a high probability of success that may not adequately reflect the execution risks.
Sign up to view all
TVTX 12-Month Price Forecast
The outlook for TVTX is a high-stakes waiting game centered on sparsentan's commercial execution. The base case (50% probability) of a successful but not spectacular launch is most likely, suggesting the stock may trade sideways as it digests its massive gains. The bull case requires flawless execution to justify further upside, while the bear case is a tangible risk given the company's leveraged balance sheet and all-or-nothing pipeline. The stance would upgrade to Bullish on evidence of sales accelerating above the average estimate or a significant debt reduction. It would turn Bearish on any confirmation of a sluggish launch trajectory or a breakdown below key technical support levels established during its consolidation.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Travere Therapeutics, Inc. Common Stock's 12-month outlook, with a consensus price target around $72.73 and implied upside of +30.0% versus the current price.
Average Target
$72.73
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$45 - $73
Analyst target range
Analyst coverage for Travere Therapeutics is limited, with only 4 analysts providing estimates, which is typical for a mid-cap biotechnology stock and can lead to higher volatility and less efficient price discovery. The average revenue estimate for the company is $1.76 billion, with a wide range from a low of $1.53 billion to a high of $2.11 billion; this 38% spread between the high and low estimates signals significant uncertainty and divergence of opinion among analysts regarding the commercial potential and launch trajectory of the company's lead drug candidate, sparsentan.
Bulls vs Bears: TVTX Investment Factors
The bull case for TVTX is powerful but narrow, hinging entirely on the flawless commercial execution of sparsentan, as evidenced by the stock's meteoric 282.7% rise and the market's pricing of a swift profitability transition (forward P/E of 11.36x). The bear case, however, highlights the extreme risks embedded in this bet: a technically overextended stock, high financial leverage (D/E of 2.86), and a binary dependency on a single drug. Currently, the bullish momentum has stronger short-term evidence, but the investment debate is defined by a single, critical tension: whether sparsentan's launch can meet the sky-high expectations already priced into the stock before financial pressures or competitive threats emerge. The resolution of this commercial execution risk will determine the stock's direction.
Bullish
- Explosive Price Momentum: The stock has gained 282.7% over the past year and 105.5% over the past three months, dramatically outperforming the SPY. This parabolic move reflects intense market anticipation for the commercial launch of its lead drug, sparsentan, for rare kidney diseases.
- Imminent Profitability Transition: The forward P/E ratio of 11.36x, based on an average analyst EPS estimate of $5.55, signals the market expects a rapid shift to profitability. This is a stark contrast to the negative trailing earnings, highlighting confidence in near-term commercial success.
- High Gross Margin Profile: The company boasts a gross margin of 97.89%, which is typical for a commercial-stage biotech and indicates strong pricing power and a scalable cost structure for its therapies. This provides a robust foundation for future profitability once sales ramp up.
- Significant Revenue Upside Potential: Analyst revenue estimates for sparsentan show a wide range, with a high estimate of $2.11 billion, 38% above the low estimate. This divergence highlights the substantial commercial optionality if the drug achieves blockbuster status in its target rare disease markets.
Bearish
- Extreme Valuation & Technical Overextension: Trading at 98.5% of its 52-week high ($55.99) after a 282.7% rally, the stock is technically overextended. Its Price-to-Sales ratio of 6.95x and negative ROE of -22.25% suggest the current price discounts near-perfect execution, leaving little room for error.
- High Financial Leverage & Unprofitability: The company carries a high debt-to-equity ratio of 2.86 and is currently unprofitable with a net margin of -5.21%. This financial structure increases risk, as the company is dependent on the success of sparsentan to service debt and fund operations.
- Binary Pipeline Dependency: The investment thesis is overwhelmingly concentrated on a single late-stage asset, sparsentan. Any clinical setback, regulatory delay, or commercial underperformance for this drug would severely damage the company's value, given its negative earnings and high leverage.
- Limited Analyst Coverage & High Volatility: With only 4 analysts providing estimates, price discovery is less efficient, which can exacerbate volatility. The stock's beta of 1.141 confirms it is 14% more volatile than the market, amplifying downside risk during sector-wide sell-offs or negative news flow.
TVTX Technical Analysis
The stock is in a powerful, sustained uptrend, having gained 282.72% over the past year, significantly outperforming the broader market. With a current price of $55.15, it is trading near the top of its 52-week range ($13.97 - $55.99), at approximately 98.5% of the range high, indicating extreme momentum and potential overextension as it tests a major resistance level. Recent momentum remains exceptionally strong, with the stock up 30.50% over the past month and 105.48% over the past three months, far exceeding the SPY's gains of 0.74% and 15.14%, respectively; this acceleration suggests the bullish trend is intensifying, likely fueled by recent positive catalysts. Key technical levels are clear, with immediate resistance at the 52-week high of $55.99 and support far below near the 52-week low of $13.97; a confirmed breakout above $55.99 could signal a continuation of the rally, while the stock's beta of 1.141 indicates it is approximately 14% more volatile than the market, which is a critical consideration for risk management given its recent parabolic move.
Beta
1.14
1.14x market volatility
Max Drawdown
-33.5%
Largest decline past year
52-Week Range
$14-$57
Price range past year
Annual Return
+286.1%
Cumulative gain past year
| Period | TVTX Return | S&P 500 |
|---|---|---|
| 1m | +25.9% | -1.6% |
| 3m | +103.0% | +11.7% |
| 6m | +38.9% | +6.3% |
| 1y | +286.1% | +22.2% |
| ytd | +41.6% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TVTX Fundamental Analysis
Revenue trajectory data is not available from the provided inputs, preventing a detailed analysis of top-line growth and segment performance. The company is not currently profitable on a net income basis, reporting negative earnings per share of -$0.0075 and a net margin of -5.21%; however, its gross margin is exceptionally high at 97.89%, which is typical for a commercial-stage biotech, indicating the primary losses are stemming from high research and development and operating expenses as it advances its pipeline. The balance sheet shows a high degree of financial leverage with a debt-to-equity ratio of 2.86, but it maintains solid short-term liquidity with a current ratio of 2.74; key cash flow and return metrics like free cash flow and ROE (which is negative at -22.25%) are not fully detailed, but the negative net income and high debt level suggest the company is likely dependent on external financing to fund its clinical development and pre-commercial activities.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TVTX Overvalued?
Given the company's negative trailing net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The stock trades at a trailing PS ratio of 6.95x, while its forward PE ratio is positive at 11.36x, indicating the market is pricing in a significant transition to profitability in the near future, as reflected in the average analyst EPS estimate of $5.55. Peer comparison data for industry average multiples is not available, so a sector-relative premium or discount cannot be quantified. Historical context for the stock's own valuation ratios is also not available in the provided data, preventing an assessment of whether the current PS ratio is near the top or bottom of its historical range.
PE
-68.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
164.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are acute. TVTX is not profitable, with a net margin of -5.21% and negative ROE of -22.25%, indicating it is burning cash to fund development and pre-launch activities. The company's high debt-to-equity ratio of 2.86 adds significant financial leverage, meaning any delay in revenue generation from sparsentan could strain its balance sheet. Furthermore, the investment is a classic 'binary event' story, with the company's fate overwhelmingly tied to the success of a single drug candidate, creating enormous concentration risk.
Market & Competitive Risks are elevated by the stock's recent parabolic move. Trading at a PS ratio of 6.95x and near its 52-week high, TVTX is vulnerable to valuation compression if growth stock multiples contract or if initial sales of sparsentan disappoint against lofty analyst estimates (which vary by 38%). The stock's beta of 1.141 indicates it will likely fall more than the market in a downturn. Competitive or regulatory threats to sparsentan's market exclusivity or pricing represent an ever-present external risk in the dynamic biopharma landscape.
Worst-Case Scenario involves a material setback for sparsentan, such as a slower-than-expected launch, payer reimbursement challenges, or emerging safety concerns. This could trigger a cascade of analyst downgrades from the current high estimates, a collapse in sentiment, and a rush for the exits. Given the stock's high volatility and recent run-up, a realistic downside could see it retrace a significant portion of its gains, potentially falling towards its 52-week low of $13.97. From the current price of ~$55.15, this represents a catastrophic loss of approximately -75%.
FAQ
The key risks are, in order of severity: 1) Commercial/Execution Risk: The company's value is overwhelmingly dependent on the successful launch of sparsentan; disappointing sales would be catastrophic. 2) Financial Risk: High debt-to-equity (2.86) and current unprofitability increase vulnerability if revenue is delayed. 3) Valuation & Volatility Risk: Trading near its 52-week high after a parabolic rally, the stock is prone to sharp corrections (beta of 1.141). 4) Pipeline Concentration Risk: Beyond sparsentan, the clinical pipeline is early-stage, offering little near-term diversification.
The 12-month forecast is bifurcated, with a base case target range of $45-$55 (50% probability), a bull case of $60-$70 (25% probability), and a bear case of $20-$35 (25% probability). The base case, which is most likely, assumes sparsentan launch proceeds in line with average analyst revenue estimates of ~$1.76 billion, leading to consolidation around current levels. The forecast hinges almost entirely on the commercial sales trajectory revealed in upcoming quarterly earnings reports, starting in Q3 2026.
TVTX appears fully valued to slightly overvalued based on current data. The primary metric is a forward P/E of 11.36x, which is not excessive for a growing biotech but implies the market already expects the company to achieve the analyst consensus EPS of $5.55. The trailing PS ratio of 6.95x also suggests a premium for growth. Without peer comparison data, the valuation is best assessed relative to its own risk profile: it prices in a high probability of commercial success, leaving little margin for error. Therefore, the stock is not clearly undervalued; it is valued for near-perfect execution.
TVTX is a speculative buy only for investors with a very high risk tolerance and a strong belief in the sparsentan launch. The stock has already surged 282.7%, pricing in significant success, and trades at a forward P/E of 11.36x. While the potential upside remains if sales beat expectations, the downside risk is severe due to high debt (D/E 2.86) and binary pipeline dependency. It is not a good buy for conservative or income-seeking investors. For aggressive growth portfolios, it could be a small, high-conviction position, but entry points are critical after such a large rally.
TVTX is unsuitable for short-term trading due to its high volatility (beta 1.141) and binary event-driven nature. It is a long-term investment for those betting on sparsentan becoming a sustainable commercial franchise over multiple years. However, 'long-term' here is conditional on successful execution; investors must be prepared to hold through significant volatility and reassess the thesis with each quarterly sales update. A minimum holding period of 2-3 years is suggested to allow the commercial story to fully unfold, but continuous monitoring is essential.